EZH2 and pachyonychia congenita: The therapeutic effects of SAM are associated with the downregulation of the ERK1/2 and STAT3 signaling pathways, both of which are involved in the survival, proliferation, migration, and invasion of cancer cells.410 EZH2, as an oncogene, is overexpressed in PC and is associated with poor clinical outcomes in PC patients.411,412 Treatment of PC cells with an AHCY inhibitor leads to the accumulation of SAH and a reduction in levels of Hcy and histone H3K27 methylation, subsequently decreasing PC cell proliferation.